William Blair Issues Optimistic Estimate for Incyte Earnings

Incyte Co. (NASDAQ:INCY) – Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $1.11 per share for the quarter, up from their prior forecast of $1.10. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%.

INCY has been the topic of several other research reports. StockNews.com downgraded shares of Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. UBS Group assumed coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price for the company. JMP Securities reissued a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. Finally, Truist Financial lowered their target price on shares of Incyte from $74.00 to $72.00 and set a “hold” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $75.13.

Incyte Trading Up 2.2 %

Shares of NASDAQ:INCY opened at $61.92 on Thursday. The stock has a 50 day moving average of $70.61 and a 200 day moving average of $70.11. The company has a market cap of $11.98 billion, a PE ratio of 229.34, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76. Incyte has a 12-month low of $50.35 and a 12-month high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling

In other Incyte news, EVP Steven H. Stein sold 12,352 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at approximately $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sheila A. Denton sold 14,069 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,914,561.36. This represents a 35.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,827 shares of company stock valued at $3,322,618 over the last 90 days. Corporate insiders own 17.60% of the company’s stock.

Hedge Funds Weigh In On Incyte

Several institutional investors and hedge funds have recently bought and sold shares of INCY. GSA Capital Partners LLP grew its position in Incyte by 26.5% during the 3rd quarter. GSA Capital Partners LLP now owns 6,453 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 1,351 shares during the last quarter. CIBC Asset Management Inc grew its holdings in Incyte by 2.9% in the third quarter. CIBC Asset Management Inc now owns 25,303 shares of the biopharmaceutical company’s stock valued at $1,673,000 after purchasing an additional 723 shares during the period. Swiss National Bank grew its stake in Incyte by 0.9% in the 3rd quarter. Swiss National Bank now owns 483,274 shares of the biopharmaceutical company’s stock valued at $31,944,000 after acquiring an additional 4,500 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Incyte during the third quarter worth about $186,000. Finally, Banque Cantonale Vaudoise raised its holdings in shares of Incyte by 336.1% during the third quarter. Banque Cantonale Vaudoise now owns 8,730 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 6,728 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.